Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 171 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Outcome Clear all
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

NCT01179048
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
9,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
125
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 21, 2026, 11:22 AM EDT
Terminated No phase listed Observational

Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)

NCT01585311
View directory record Official record
Conditions
Subarachnoid Hemorrhage (SAH), Tachycardia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

NCT03057951
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,988 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
161
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study

NCT02492269
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Aymen N Naguib
Other
Eligibility
1 Month to 12 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 21, 2026, 11:22 AM EDT
Not listed No phase listed Observational

Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit

NCT01618123
View directory record Official record
Conditions
Myocardial Infarction, Death, Cerebrovascular Accident, Congestive Heart Failure, Angina Pectoris
Interventions
Not listed
Lead sponsor
Sheba Medical Center
Government
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 21, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 21, 2026, 11:22 AM EDT
Not listed No phase listed Observational

The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation

NCT05012605
View directory record Official record
Conditions
Stroke, Sleep Wake Disorders, Rehabilitation, Recovery of Function
Interventions
Observation
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2021 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Kansas • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jul 21, 2026, 11:22 AM EDT
Completed No phase listed Observational Results available

Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care

NCT00783302
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 21, 2026, 11:22 AM EDT
Completed No phase listed Observational

Imaging Modalities in Detection of Coronary Artery Disease in End-stage Renal Disease Patients

NCT00726921
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction, Stroke, Death
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 21, 2026, 11:22 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) to Evaluate Brain Injury in Congenital Heart Disease

NCT00932633
View directory record Official record
Conditions
Neonatal Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Days
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

NCT00630396
View directory record Official record
Conditions
Stroke, Acute
Interventions
Minocycline
Drug
Lead sponsor
David Hess, MD
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Lexington, Kentucky • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

NCT03036150
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
55
States / cities
Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 21, 2026, 11:22 AM EDT
Terminated Not applicable Interventional

Above-Knee-High Application of Lower Limb Compression and Its Impact on Clinical Outcome in Patients Hospitalized With Heart Failure Exacerbation.

NCT05467735
View directory record Official record
Conditions
Heart Failure; With Decompensation, Lower Extremity Edema, Heart Failure，Congestive
Interventions
Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

NCT00853658
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Enalapril, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
58
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Jul 21, 2026, 11:22 AM EDT
Completed No phase listed Observational

SYNCHRONISE: LVO Triage Timing and Outcome Study

NCT04608617
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Viz LVO (De Novo Number DEN170073), Baseline Effectiveness Cohort
Device · Other
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • Memphis, Tennessee • Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 11:22 AM EDT
Completed No phase listed Observational

Neurological Outcome With Carotid Artery Stenting

NCT00597974
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis, Stroke, Transient Ischemic Attack
Interventions
Angioplasty, Stent, Neurological and neuropsychological evaluations, Angiography
Procedure · Device · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

NCT01990768
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Jul 21, 2026, 11:22 AM EDT
Withdrawn Not applicable Interventional

Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

NCT01076140
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Lisinopril
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Jul 21, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Hub and Satellite" Heart Failure Provider's Network Study

NCT01246050
View directory record Official record
Conditions
Heart Failure
Interventions
HF training, No HF training
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Jul 21, 2026, 11:22 AM EDT
Completed No phase listed Observational

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718
View directory record Official record
Conditions
Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
44,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 11:22 AM EDT
Not listed No phase listed Observational

The Diabetic Foot Ulcer Registry

NCT02813161
View directory record Official record
Conditions
Diabetic Foot Ulcer Outcome, Quality of Patient Care
Interventions
cellular and tissue based therapy, negative pressure wound therapy, debridement, advanced wound therapy, Nutritional screening, off-loading, Hyperbaric oxygen Therapy
Biological · Device · Procedure + 1 more
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Jul 21, 2026, 11:22 AM EDT